A Phase I Study of BTX-1188 in People with Acute Myeloid Leukemia

Share

Full Title

An Open-Label, Escalating Multiple-Dose Study to Evaluate the Safety, Toxicity, Pharmacokinetics, and Preliminary Activity of BTX-1188 in Subjects with Advanced Malignancies

Purpose

The purpose of this study is to find the highest dose of the investigational drug BTX-1188 that can be used to treat people with acute myeloid leukemia (AML) that has come back or continued to grow despite prior treatment. BTX-1188 is designed to target and destroy two proteins that promote the growth and survival of cancer cells. It is taken orally (by mouth).

Eligibility

To be eligible for this study, patients must meet several requirements, including:

  • Participants must have AML that has come back or continued to grow despite standard treatments.
  • At least 2 weeks must pass since the completion of previous therapies and receipt of BTX-1188.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for people age 18 and older.

For more information and to ask about eligibility for this study, please contact the office of Dr. Eytan Stein at 646-608-3719.

Protocol

22-102

Phase

I

Disease Status

Relapsed or Refractory

Investigator

Co-Investigators